RT Journal Article
SR Electronic
T1 Amylase α-2A Autoantibodies
JF Diabetes
JO Diabetes
FD American Diabetes Association
SP 732
OP 737
DO 10.2337/db08-0493
VO 58
IS 3
A1 Endo, Toyoshi
A1 Takizawa, Soichi
A1 Tanaka, Shoichiro
A1 Takahashi, Masashi
A1 Fujii, Hideki
A1 Kamisawa, Terumi
A1 Kobayashi, Tetsuro
YR 2009
UL http://diabetes.diabetesjournals.org/content/58/3/732.abstract
AB OBJECTIVE— The pathogenesis of autoimmune pancreatitis (AIP) and fulminant type 1 diabetes remains unclear, although it is known that immune-mediated processes severely compromise the endocrine and exocrine functions in both diseases.RESEARCH DESIGN AND METHODS— We have screened a λTriplEx2 human pancreas cDNA library with serum from a patient with AIP and obtained positive clones. Sequence analysis revealed that 7 of 10 clones were identical to human amylase α-2A. Using a recombinant COOH-terminal amylase α-2A protein, we developed an enzyme-linked immunosorbent assay system to detect autoantibodies against human amylase α-2A.RESULTS— All 15 serum samples from patients with AIP recognized the recombinant protein, whereas sera from 25 patients with chronic alcoholic pancreatitis and sera from 25 patients with a pancreas tumor did not. Interestingly, 88% (15/17) of patients with fulminant type 1 diabetes were positive for an autoantibody against amylase α-2A. These antibodies were detected in 21% of patients with acute-onset type 1 diabetes (9 of 42) and 6% of type 2 diabetic patients (4 of 67).CONCLUSIONS— These results suggest that an autoantibody against amylase α-2A is a novel diagnostic marker for both AIP and fulminant type 1 diabetes and that, clinically and immunologically, AIP and fulminant type 1 diabetes are closely related.